Supplement Aims and Scope
This supplement is intended to focus on drug eluting devices. Devices (eg cardiovascular
stents, drug delivery biopolymers and tissue engineering devices), their bio-compatibility,
and mechanisms of transport are included within the supplement’s scope.
Drug Target Insights aims to provide researchers working in this complex, quickly
developing field with online, open access to highly relevant scholarly articles by
leading international researchers. In a field where the literature is ever-expanding,
researchers increasingly need access to up-to-date, high quality scholarly articles
on areas of specific contemporary interest. This supplement aims to address this by
presenting high-quality articles that allow readers to distinguish the signal from
the noise. The editor in chief hopes that through this effort, practitioners and researchers
will be aided in finding answers to some of the most complex and pressing issues of
our time.
The rapidly expanding panorama of prosthetic replacement and interventional procedures
for cardiovascular disease demands significant research for the development of devices
with optimized characteristics and performance to overcome the drawbacks of the existing
strategies. Tissue engineering is a potent weapon in this scenario, enabling the realization
of sophisticated biocompatible devices interacting with the host tissues and influencing
their behavior. The fabrication and design of “smart” biomaterials, able to sense
and interact with the biological milieu, represent a cornerstone in tissue engineering
and regenerative medicine. This development has demolished the obsolete tenets of
surgery implying reconstructing organs or part of them with artificial materials.
The deeper understanding achieved by modern research has highlighted the limitations
and the biological and clinical drawbacks of the long-term coexistence of a foreign
material in the body, especially in the cardiovascular system.1 The need to respect
the physiological reparative and remodeling processes normally occurring in nature
progressively achieved significance in the current research,2,3 demonstrating the
necessity to accompany the body’s physiological responses and the activities of tissue
regeneration rather than pretending to replace them with “plastic” surrogates. This
attention to the biology of regeneration in tissue engineering and to micro-environmental
conditions at the tissue and cellular levels is expressed in the articles of this
special issue of Drug Target Insights. Interesting and sophisticated approaches are
proposed in this context, entailing the use of drug-delivery devices that release
tailored compounds to target specific aspects of diseases or complications. In this
issue, Dr Rapetto and colleagues extensively reviewed the role of gentamicin-impregnated
collagen sponges (GICSs) in preventing sternal wound infection. The use of these delivery
devices allows for topical delivery of high antibiotic concentrations to the wound,
reducing the complications associated with gentamycin toxicity.4 On the other side,
alternative use of smart biopolymers able to release anticoagulant agents, such as
heparin, to avoid early vascular graft thrombosis and failure will be presented and
discussed in the same issue of the Journal.5 These are not the only applications in
this field, as demonstrated by other papers in this issue. Indeed, at the experimental
level, several research efforts have been engaged in designing scaffold-releasing
factors, drugs or cytokines to improve tissue regeneration or stem cell recruitment,
or to overcome prosthesis-related issues.6 The possibility to tailor a bioresorbable
scaffold in order to create a microenvironment able to boost or guide tissue regeneration
is an exciting area of investigation.7,8 Additionally, drug-releasing devices might
also allow avoidance or treatment of some of the drawbacks related to prosthetic replacement
of cardiovascular structures.5,6
In the field of interventional cardiology there is a widespread use of drug-releasing
stents, in particular of steroids or antiproliferative agents in order to prevent
neointimal hyperplasia. Interestingly, the concept of paracrine or local release of
molecules with modulatory or homeostatic action is not new in biology. Endothelium-mediated
release of growth factors and regulatory molecules is a well-accepted natural mechanism
to locally and remotely control or respond to a variety of physiological or pathological
conditions, and different parts of the vascular tree might behave differently according
to their biological needs. This concept has important ramifications also in the clinical
side, especially when treating cardiovascular structures. Release of drug from coronary
stents (drug-eluting stents, DES) able to influence or modify endothelial homeostasis
and function is an example. More interestingly, the use of autologous non-artificial
conduits in coronary artery bypass graft (CABG) surgery might be considered another
intriguing system of “natural” drug delivery device. CABG might be performed using
autologous saphenous vein or internal thoracic artery (ITA or mammary artery), two
conduits with profoundly different biological features and structure. There is a general
consensus on the accelerated degeneration of venous grafts after surgery, with extremely
high incidence of failure and lower patency rates in comparison to arterial grafts.
This difference in angiographic patency was shown to be associated with improved clinical
outcomes and rates of ischemia-free survival in patients undergoing exclusive arterial
revascularization, especially in case of subjects who previously developed in-stent
restenosis.9 Construction of coronary graft through the use of arterial conduits,
especially with internal thoracic artery (ITA), is therefore advocated as desirable
to ensure long-term patency and optimal clinical outcomes.10,11
The biological mechanisms underlying the poorer outcomes of venous grafts in respect
to arterial ones are not well understood and still a matter of debate. Reduced production
of nitric oxide has been claimed as a primary factor,12 implicated in venous graft
failure in relation to established risk factors for atherosclerosis;13 also, differences
in thrombin receptor expression between arterial and venous grafts have been demonstrated,14
and deregulation of these receptors has been associated with in-stent restenosis.15
Nitric oxide production is not reduced in arterial grafts and particularly the ITA,
even with severe atherosclerotic disease, and this is thought to be one of the factors
in the superior outcome of these conduits.16 Additionally, it has been shown that
the structure of the ITA itself is able to better adapt to arterial pressures and
its endothelium responds to high flow rates with a higher amount of nitric oxide,
providing superior reactivity to flow requirements in the coronary arteries when used
as a graft in CABG.17
On this basis, ITA might be considered as a “drug-eluting” graft as it is able to
release into the grafted myocardium nitric oxide, providing important signaling to
prevent graft failure and ameliorate cardiac function. Clearly, the biology underlying
this process is far more complex and is not restricted to a single compound, but most
probably involves a wide spectrum of molecules interacting to determine the biological
effects seen both experimentally and clinically.
Proteomics studies allow for a comprehensive analysis and identification of the complete
protein pattern of a tissue or fluid,18,19 and some studies performed using this approach
showed the presence in human arterial smooth muscle of small leucine-rich proteoglycans
involved in collagen fibrillogenesis, and of some non-fibrillar collagens in combination
with alterations of several other proteins. This has been considered as a marker of
arterial stiffness and therefore increased risk of developing atherosclerosis.20 Structural
proteomic studies on ITA tissue showed differential expression of proteins that are
implicated in cytoskeleton activity regulation,21 in the migrative capacity of vascular
smooth muscle cells, extracellular matrix composition, coagulation, apoptosis, and
heat shock response.22 Interestingly, a proteomic analysis of the secrete of ITA,
known as secretome, demonstrated an increased production of gelsolin, vinculin, lamin
A/C and phosphoglucomutase 5 by mammary arterial tissues. These proteins are also
involved in the regulation of important intracellular mechanisms related to cell migration,
ECM deposition and smooth muscle phenotype switching, which are crucial steps in atherosclerosis
pathogenesis.23 The expression of specific groups of proteins in the ITA is claimed
to be the basis of the relative protection of this vessel from the onset and progression
of atherosclerosis, and subsequently of its beneficial effects when is used as a graft
for coronary artery in terms of recurrence of heart disease.22,23 From these studies,
we might reliably speculate that when used in the context of CABG, the ITA exerts
a “paracrine activity” liberating locally and within the blood stream factors that
are able to maintain a positive vascular homeostasis, thereby avoiding disease recurrence
in the grafted coronary and permitting high patency rate of the bypass in the long
term. Considering the significant difference in patency rate when conduits different
from ITA are used, more complex mechanisms should be underlying ITA selective advantage
in CABG. Use of proteomics and redox-proteomics approaches to simultaneously compare
the protein profile of ITA, saphenous vein grafts and aorta, another tissue prone
to atherosclerosis, has been advocated to better understand differences among the
conduits. Also, these investigations might be extended to the secretomes of these
conduits in order to have a paracrine correlate to the targets found in the respective
tissues. Differential profiles of protein expression exclusively present in ITA tissues
and secrete, but not in the other vessels, have been intriguingly discovered (Fig.
1) and the identification of these proteins would provide in the future precious information
to elucidate reasons of ITA superiority in CABG. Moreover, the identification of these
proteins would enable more significant clinical applications. The factors produced
by the ITA, and considered at the basis of the maintenance of graft patency and protection
from atherosclerosis recurrence, might constitute in the future “drugs” to be administered
to patients or eluted in stents or delivery devices. Conversely, factors identified
from saphenous tissue, which are clinically associated to poor outcomes and failure
of the grafts, might represent targets for design of specific compounds with inhibitory
or blocking effects.
In the field of drug-eluting devices, a close observation and attention to the naturally
occurring phenomena might provide us with a range of therapeutic options wider than
any other drug currently used in DES or tissue engineering approaches. For example,
the ITA naturally carries a regulated set of factors, finely modulated and intertwined,
which protects against atherosclerosis and can be therefore considered the best drug-eluting
device available at the moment in cardiovascular disease.
In conclusion, with the increase in life expectancy and in the morbidities related
to chronic diseases, smarter weapons are required to control pathology. The exciting
field of drug delivery devices might provide novel strategies and open new avenues
in the treatment of cardiovascular disease. In this context, scientists might need
to realize that the endogenous and physiologically-occurring release of paracrine
factors by the native tissues might be a “system” to better understand and to target
when constructing new drug-releasing devices.
Lead Guest Editor Dr. Cristiano Spadaccio
Clinical Lecturer at the Institute of Cardiovascular and Medical Science of the University
of Glasgow and holds a clinical position of cardiothoracic surgical fellow at the
cardiothoracic surgery department of the Golden Jubilee National Hospital. He completed
his PhD at University La Sapienza of Rome and has previously worked at the McGowan
Institute for Regenerative Medicine at the University of Pittsburgh Medical Center
(USA), the New York Presbyterian and Columbia University Hospital (USA), the Cardiovascular
surgery department of University of Leuven (Belgium), the Campus St Jan Hospital Osot-Limburg
in Genk (Belgium) and at the University Campus Bio-Medico of Rome, Italy. He now works
primarily in the field of translational research and clinical in cardiovascular surgery,
in tissue engineering and regenerative medicine. Dr. Spadaccio is the author or co-author
of more than 60 PubMed-indexed published papers and has presented more than 60 abstracts
and personal communications at conferences, being involved in organization of meetings
and chairing of sessions as moderator. He holds editorial appointments at the journal
Artificial Organs.
cristianospadaccio@gmail.com
Institutional webpage
http://www.gla.ac.uk/researchinstitutes/icams/staff/?action=person&id=4edcedec8393
Guest Editors
DR. NICOLA TESTA
Cardiovascular Surgeon of Italy at John Paul II Foundation—Catholic University in
Campobasso. He completed his MD degree at Catholic University of Sacred Heart in Rome
(2003) and Cardiac Surgery Residency at Catholic University of Sacred Heart in Rome
(2008) He has previously worked as Staff Cardiac Surgeon in Cardiovascular Surgery
Unit—Catholic University in Campobasso (2008–2013) and in Cardiac Surgery Unit “SS.Annunziata
Hospital” Chieti (2013–2014). He now works primarily in heart failure treatment and
research and surgical atrial fibrillation ablation. Dr. Testa is the author or co-author
of more than 30 published papers and has presented at more than 30 conferences.
ntesta.cch@gmail.com
Institutional webpage
http://www.fgps.it/index.php/i-dipartimenti/malattie-cardiovascolari-e-dei-grossi-vasi/personale
DR. FRANCESCO NAPPI
Cardiovascular surgeon at Centre Cardiologique du Nord, Paris, France. He completed
his MD at University Federico II of Naples and has previously worked as a surgeon
and as a researcher in this institution. He now works primarily in cardiovascular
disease and translational medicine. Dr. Nappi is the author or co-author of 40 published
papers and has presented at over 30 conferences, and holds editorial appointments
at the Journal of Thoracic Disease.
francesconappi@gmail.com
DR. ALBERTO RAINER
Assistant professor in Chemical Fundamentals of Technologies at Università Campus
Bio-Medico di Roma, Italy. He completed his PhD at University Tor Vergata of Rome
and has previously worked at the University of Rome and Triest. He now works primarily
in tissue engineering, biofunctionalization of polymers and analysis of cell-to-cell
interaction on micro chips. Dr. Rainer is the author or co-author of over 30 published
papers and has presented at over 40 conferences, and holds editorial appointments
at the journal Artificial Organs.
rainer@unicampus.it
Institutional webpage
http://didattica.unicampus.it/didattica/Guide/PaginaDocente.do;jsessionid=BB5DF6E681779E9A0D9EE809D4665E1A.jvm1a?docente_id=325
DR. VITO D. BRUNO
Senior Registrar in Cardiac Surgery at University Hospitals of Bristol and Research
Associate fellow at the department of Clinical Science at University of Bristol (UK).
He completed his PhD in Surgery and Surgical Biotechnology at University of Insubria,
Varese (Italy). He has previously worked at Varese University Hospital (Varese—Italy)
and Cardiocentro Ticino (Lugano—Switzerland.) He now works primarily in clinical and
translational research in cardiac surgery and cardiology. Dr. Bruno is the author
or co-author of 23 Pubmed cited papers and more than 30 abstracts for national and
international meetings. He is section editor at Archives of Medical Science—Civilisation
Disease.
mddvb@bristol.ac.uk
Institutional webpage
http://www.bris.ac.uk/clinical-sciences/people/182709/index.html